Prevalence of potential drug-drug interactions in bone marrow transplant patients

International Journal of Clinical Pharmacy

Volumn 33, Issue 6, 2011, Pages 1002-1009

  Guastaldi, Rosimeire Barbosa Fonseca ^a   Reis, Adriano Max Moreira ^b   Figueras, Albert ^c   Secoli, Silvia Regina ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Fundacion Institut Catala de Farmacologia   (Spain)

Author keywords

Bone marrow transplantation; Brazil; Drug utilization; Drug drug interactions; Medication safety; Pharmacotherapy

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMLODIPINE; ANTICONVULSIVE AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DIAZEPAM; FENTANYL; FLUCONAZOLE; FUROSEMIDE; HYDROCORTISONE; LEVOFLOXACIN; MELPHALAN; METOCLOPRAMIDE; MORPHINE; NAPROXEN; OMEPRAZOLE; ONDANSETRON; PARACETAMOL; PHENYTOIN; SERTRALINE;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; ARTICLE; ATAXIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; BRAZIL; CARDIOTOXICITY; CHOLESTASIS; CONTROLLED STUDY; CROSS SECTIONAL STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; HEART ARREST; HUMAN; HYPERREFLEXIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEPHROTOXICITY; NYSTAGMUS; OUTCOME ASSESSMENT; PARESTHESIA; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATION DEPRESSION; SEDATION; SEIZURE; SIDE EFFECT; STUDY DESIGN; TERTIARY HEALTH CARE; TESTIS CANCER; TORSADE DES POINTES; TREATMENT DURATION; TREMOR;

ADULT; AGED; BONE MARROW TRANSPLANTATION; BRAZIL; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PREVALENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 83255187171     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-011-9574-2     Document Type: Article

References (28)

1. Fuhr U. Improvement in the handling of drug-drug interactions. Eur J Clin Pharmacol. 2008;64:167-71.
2. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6(7):546-58. (Pubitemid 43980543)
3. Van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011. (ahead of print). doi:10.1093/annonc/mdq761.
4. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007; 99(8):592-600. (Pubitemid 47073540)
5. Mihara A, Mori T, Aisa Y, Yamazaki R, Iketani O, Tanigawara Y, Ikeda Y, Okamoto S. Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole. Eur J Clin Pharmacol. 2008;64:89-91.
6. Secoli SR, Figueras A, Lebrão ML, Lima FD, Santos JL. Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging. 2010;27: 759-70.
7. Nagamura F, Takahashi T, Takeuchi M, Iseki T, Ooi J, Tomonari A, Uchimaru K, Takahashi S, Tojo A, Tani K, Asano S. Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32:1051-8. (Pubitemid 37540734)
8. Egger SS, Meier S, Leu C, Christen S, Gratwohl A, Krähenbühl S, Haschke M. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant. 2010;45:1197-203.
9. Klasco RK editor. Drug Reax® System. Thomson Micromedex, Greenwood Village, Colorado, USA. Available on: http://www. periodicos.capes.gov.br Accessed 28 June 2008.
10. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci. 2008;30(4):367-374. doi:10.1007/s11096-008-9191-x.
11. Reis AMM, Cassiani SHB. Evaluation of three brands of drug interaction software for use in intensive care units. Pharm World Sci. 2010;32(6):822-828. doi:10.1007/s11096-010-9445-2.
12. World Health Organization. Collaborating Center for Drug Statistics Methodology. ATC/DDD Index 2011. Available from URL: http://www.whocc.no/atcddd/ index. Accessed 04 Aug 2011.
13. Riechelmann RP, Zimmermann C, Chin SN, Wang L, O'Carroll A, Zarinehbaf S, Krzyzanowska MK. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symp Manag. 2008;35:535-43.
14. Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant. 2004;33:137-52. (Pubitemid 38180925)
15. Freeman DL, Laupacis A, Keown PA, Stiller CR, Carruthers SG. Evaluation of cyclosporine - phenytoin interaction with observations on cyclosporine metabolites. Br J Clin Pharmacol. 1984;18(6):887-93. (Pubitemid 15190526)
16. Keown PA, Laupacis A, Carruthers G, Stawecki M, Koegler J, McKenzie FN, Wall W, Stiller CR. Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation. 1984;38(3):304-6. (Pubitemid 14035185)
17. Ng TM, Bell AM, Hong C, Hara JM, Touchette DR, Danskey KN, Lindsay TT, Puumala SE. Pharmacists monitoring of QTc interval - prolonging medications in critically ill medical patients: a pilot study. Ann Pharmacother. 2008;42:475-82. (Pubitemid 351521960)
18. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug related QT interval prolongation. Pharmacotherapy. 2003;23:881-908. (Pubitemid 36875672)
19. Gandhi PJ, Menezes PA, Vu HT, Rivera AL, Ramaswamy K. Fluconazol and levofloxacin - induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm. 2003;60: 2479-83. (Pubitemid 44712868)
20. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730-44. (Pubitemid 44885328)
21. Yu DT, Peterson JF, Seger DL, Gerth WC, Bates DW. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf. 2005;14:755-67. (Pubitemid 41684468)
22. Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dosedependent effect? Ann Pharmacother. 1993;27:427-30.
23. Egger SS, Drewe J, Shlienger RG. Potential drug-drug interactions in the mediation of medical patient at hospital discharge. Eur J Clin Pharmacol. 2003;58:773-8. (Pubitemid 36399235)
24. Delafuente JC. Understanding and preventing drug-drug interactions in elderly patients. Critic Rev Oncol Hematol. 2003;48: 133-43. (Pubitemid 37357294)
25. Zwart-van Rijkom J, Uijtendaal E, Ten Berg M, Van Solinge W, Egberts A. Frequency and nature of drug-drug interactions in a Dutch university hospital. Br J Clin Pharmacol. 2010;68(2): 187-93.
26. Leone R, Magro L, Moretti U, Cutroneo P, Moschini M, Motola D, Tuccori M, Conforti A. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf. 2010;33(8):667-75.
27. Cruciol-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics. 2006;61(6):515-20.
28. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Recognition and management of potential drug-drug interactions in patient on internal medicine wards. Eur J Clin Pharmacol. 2007;63: 1075-83. (Pubitemid 47561805)